Dimerix (ASX: DXB) acquires Phase 2-ready DMX-652 as acute kidney injury deal reshapes renal pipeline

Dimerix Limited (ASX: DXB) has acquired global rights to DMX-652, formerly known as MTX652, from United Kingdom-based Mission Therapeutics Limited for an upfront payment of US$5 million and a series of contingent development, approval and sales payments. The orally administered small molecule targets USP30, a mitochondrial enzyme, and will initially be developed to prevent acute kidney injury in patients undergoing high-risk cardiac surgery. The transaction gives Dimerix an open United States Investigational New Drug application, a Food and Drug Administration-cleared Phase 2 protocol, clinical-grade drug supplies, manufacturing methods and intellectual property expected to extend to 2041. The acquisition broadens Dimerix beyond focal segmental glomerulosclerosis while creating a potential interim clinical readout during 2027. The main tension is whether Dimerix can convert a previously delayed programme into a productive second clinical franchise without distracting capital and management attention from DMX-200’s pivotal ACTION3 Phase 3 trial.

Dimerix plans a multicentre, double-blind and placebo-controlled Phase 2 study involving approximately 160 adults at high risk of acute kidney injury following cardiac surgery. Clinical-site initiation and ethics approval are targeted for the second half of 2026, with the first patient expected to be dosed during the first half of 2027 and an interim data readout anticipated before the end of 2027. The study’s primary endpoint will evaluate the incidence of acute kidney injury seven days after surgery.

Why does acquiring DMX-652 change Dimerix’s risk profile beyond simply adding another kidney drug?

Until this transaction, Dimerix’s valuation and development outlook were overwhelmingly tied to DMX-200 and the ACTION3 trial in focal segmental glomerulosclerosis. The adult ACTION3 cohort is fully recruited, with 333 patients randomised and dosed across a global trial network, but the last adult patient is not expected to complete the two-year treatment period until March 2028. Dimerix and its commercial partners have elected to continue the trial through its final proteinuria endpoint rather than pursue a shorter and potentially riskier regulatory pathway.

DMX-652 changes that timing profile by introducing a separate clinical programme with an interim readout expected in 2027. That potentially gives Dimerix a clinically meaningful catalyst before the ACTION3 trial reaches full completion, reducing the extent to which the company’s news flow depends on one long-duration study.

The diversification is not complete protection against clinical risk. Both programmes remain experimental kidney therapies, and neither has regulatory approval. However, they address different disease settings, operate through different biological mechanisms and sit at different clinical stages. DMX-200 targets chronic rare kidney disease, while DMX-652 initially targets an acute complication associated with cardiac surgery.

This creates a more balanced development portfolio, but it also changes Dimerix’s operating requirements. The company must now manage a pivotal global Phase 3 programme, prepare a new Phase 2 study, maintain relationships with five commercial partners and evaluate additional renal opportunities. The acquisition improves pipeline depth, but its value depends on whether Dimerix can expand without losing focus.

What exactly has Dimerix acquired from Mission Therapeutics and how close is DMX-652 to Phase 2?

The transaction transfers sole ownership and development control of DMX-652 across all potential indications. Dimerix will receive the candidate’s composition-of-matter patent family, an exclusive licence to supporting background patents, the open United States Investigational New Drug application, the Food and Drug Administration-cleared Phase 2 protocol and sufficient pharmaceutical-grade product for the proposed study. Manufacturing processes developed for the asset are also included.

Those components reduce several early development barriers. Dimerix does not need to begin with a new Phase 1 programme, establish an initial safety profile or develop an entirely new clinical manufacturing process before preparing the next trial.

Mission Therapeutics completed a Phase 1 study involving 85 healthy volunteers. DMX-652 was tested in single doses of up to 200 milligrams and repeated daily doses of up to 100 milligrams for 14 days. Dimerix reported that the compound was well tolerated, with no drug-related serious adverse events and a pharmacokinetic profile considered suitable for further clinical development.

The asset remains Phase 2-ready rather than clinically validated in acute kidney injury. Its completed human data establish initial safety and exposure information in healthy volunteers, not efficacy in cardiac-surgery patients. The proposed 160-patient trial will be the first meaningful test of whether USP30 inhibition can reduce kidney injury in the intended clinical population.

The existing drug supply and open Investigational New Drug application could shorten preparation time, but Dimerix must still secure ethics approvals, activate sites, recruit suitable patients and deliver consistent dosing around complex surgical procedures. The practical value of the acquired package will be measured by how quickly the company can move from contractual ownership to first-patient dosing.

Why has the original MTX652 clinical timetable slipped despite receiving FDA clearance in 2023?

Mission Therapeutics announced United States Food and Drug Administration clearance for the proposed Phase 2 study in December 2023 and initially expected the trial to begin in early 2024. In March 2024, Mission described MTX652 as being in Phase 2 development for cardiac surgery-associated acute kidney injury. Dimerix’s current schedule, however, places site initiation in the second half of 2026 and first-patient dosing in the first half of 2027.

Neither Dimerix’s acquisition announcement nor Mission Therapeutics’ recent public materials provided a detailed explanation for why the previously anticipated study did not begin on the original timetable. The programme therefore arrives with valuable regulatory and manufacturing work already completed, but also with a development delay that warrants attention.

The delay does not establish a problem with the compound itself. Clinical programmes can be postponed for financing, strategic, manufacturing, operational or portfolio-prioritisation reasons. Mission continued to advance its broader USP30 platform and raised additional capital in 2024, while later focusing fresh funding on its Parkinson’s disease candidate MTX325.

Dimerix now has an opportunity to restart the programme within a renal-focused organisation. Its experience with global kidney-disease investigators, trial sites, regulators and commercial partners could provide a more natural operating home for the asset.

The first-patient date will nevertheless be an important credibility test. A smooth start during the first half of 2027 would show that the acquired clinical package is genuinely deployment-ready. Further delay would reduce the strategic benefit of having purchased a programme promoted as capable of rapid Phase 2 advancement.

How does USP30 inhibition differ from DMX-200 and why could that matter clinically?

DMX-652 is designed to inhibit USP30, an enzyme that can restrict mitophagy, the process through which cells identify and remove damaged mitochondria. By inhibiting USP30, the candidate is intended to support mitochondrial quality control and reduce the cellular consequences of oxygen deprivation, toxin exposure, sepsis and subsequent tissue injury.

Cardiac surgery provides a potentially useful initial clinical setting because the timing of the kidney injury risk is relatively predictable. Cardiopulmonary bypass and valve procedures may expose kidney tissue to reduced blood flow followed by reperfusion when oxygenated circulation returns. Dimerix intends to administer DMX-652 around this defined period and measure whether the treatment lowers acute kidney injury incidence over the following seven days.

DMX-200 has a different mechanism. It is a CCR2 antagonist administered alongside an angiotensin receptor blocker and is being evaluated for its ability to reduce proteinuria and preserve kidney function in patients with focal segmental glomerulosclerosis. The two candidates therefore target different biological processes and patient groups.

That distinction improves the strategic logic of the acquisition. Dimerix is not simply purchasing another version of its existing programme. It is adding a therapy aimed at the acute end of kidney injury while DMX-200 addresses a chronic, progressive and rare glomerular disease.

Dimerix has characterised DMX-652 as a potential first-in-class candidate and said it was not aware of another clinical-stage competitor using the same mechanism for acute kidney injury. That remains a company assessment rather than evidence that DMX-652 will deliver superior clinical outcomes. The Phase 2 study must demonstrate that a scientifically credible mitochondrial mechanism produces a measurable patient benefit.

Can Dimerix fund DMX-652 without weakening the ACTION3 Phase 3 programme?

Dimerix ended the March 2026 quarter with A$26.6 million in cash after recording net operating cash outflows of A$11.5 million. The expenditure was primarily associated with clinical recruitment and manufacturing, and the company has repeatedly noted that trial spending is uneven between quarters.

The company said completion of the DMX-200 ACTION3 trial, payment of the DMX-652 upfront consideration and initiation of the new Phase 2 trial are funded through existing cash, an approximately A$14 million upfront payment due from Everest Medicines and a binding A$10 million funding facility. Drawdown of the A$10 million facility is at Dimerix’s discretion, meaning it represents available funding rather than cash already received.

Everest Medicines agreed in June 2026 to license DMX-200 in Greater China, South Korea and Southeast Asia. The agreement added another regional commercial partner and provided a near-term non-dilutive cash contribution to Dimerix’s development plan.

Dimerix is also negotiating access to up to a further A$40 million of non-dilutive funding. The company said this additional capital could extend its runway beyond ACTION3 completion and support a broader development pipeline. Those negotiations are not yet completed and should not be treated as committed liquidity.

The funding structure reduces immediate equity-dilution pressure, but it does not make the acquisition costless. The US$5 million upfront payment must be made within 30 days, while clinical-trial expenses will increase as site activation and recruitment progress. Any loan drawdown will also introduce contractual repayment obligations.

The important capital-allocation question is whether Dimerix can preserve enough flexibility for DMX-200 manufacturing, regulatory preparation and partner support while progressing DMX-652. The acquisition is more compelling if it uses existing renal infrastructure efficiently. It becomes less attractive if the second programme materially raises overhead or forces a future capital raise before either asset delivers decisive data.

Do the milestone and royalty terms leave enough economics for Dimerix if DMX-652 succeeds?

Beyond the US$5 million upfront payment, Dimerix could owe Mission Therapeutics up to US$47 million following predefined clinical-development achievements, US$40 million upon marketing approval, US$25 million if the compound is approved in a second indication and up to US$175 million in sales-related milestones. Including the upfront amount, the disclosed contingent transaction value can reach US$292 million before royalties.

The majority of those payments become relevant only if DMX-652 advances successfully. This limits the amount Dimerix must commit before clinical validation, but it also means substantial value will be shared with Mission if the programme reaches approval and commercial scale.

Dimerix will pay royalties of 8% to 10% on global net sales it generates directly. Where a third-party sublicensee commercialises the product, the applicable royalty to Mission will be 2.5% to 5% of net sales.

These obligations do not automatically make the acquisition expensive. A product capable of supporting large development and sales milestones would, by definition, have achieved significant clinical and commercial progress. The relevant question is how much retained economics Dimerix can generate after development costs, partner payments, milestone obligations and royalties.

The structure may encourage a partnering strategy similar to DMX-200. Dimerix can develop the asset through a value-inflection point and then license regional or global rights to a larger pharmaceutical company. That could reduce its direct commercial expenditure, although a sublicense would also divide future economics among Dimerix, Mission Therapeutics and the commercial partner.

What does the DXB share-price reaction reveal about investor expectations after the acquisition?

Dimerix shares traded at A$0.26 by 11:29 a.m. Australian Eastern Standard Time on 17 July, up 6.3% after reopening from a trading halt. The stock traded between A$0.25 and A$0.27, with approximately 4.26 million shares changing hands by that point.

The intraday price was around 8% above the A$0.24 close recorded on 10 July and approximately 37% above the A$0.19 close on 17 June. Dimerix nevertheless remained about 61% below its 52-week high of A$0.665, with the available annual range extending down to A$0.158.

The positive movement indicates increased attention following the acquisition and funding announcements, but the response was measured rather than euphoric. The market appears to recognise the benefit of adding another clinical asset while retaining caution around the long development timeline, milestone obligations and lack of human efficacy data in acute kidney injury.

At A$0.26, Dimerix’s implied market value was approximately A$156 million based on roughly 600.4 million shares outstanding. That valuation remains principally supported by expectations for DMX-200, the company’s licensing portfolio and future clinical results rather than revenue from approved products.

A sustained rerating would probably require more than completing the acquisition payment. Investors will need evidence that the Phase 2 study begins on schedule, enrolment is practical and early data support the biological rationale.

Which milestones will show whether Dimerix’s DMX-652 acquisition is creating lasting value?

The immediate milestones are transfer of the intellectual property and regulatory documentation, payment of the US$5 million upfront consideration and completion of operational preparations for the Phase 2 study.

Ethics approval and clinical-site initiation during the second half of 2026 will show whether the programme can restart without significant additional delay. First-patient dosing during the first half of 2027 will be the clearest evidence that Dimerix has successfully converted an acquired regulatory package into an active clinical programme.

The 2027 interim analysis will then become the central value test. A reduction in acute kidney injury incidence, supported by an acceptable safety profile and consistent secondary measures, could validate USP30 inhibition in a major unmet medical need and create opportunities in additional kidney or mitochondrial disorders.

An inconclusive or negative result would limit the value of the asset and leave Dimerix more dependent on DMX-200. Slower enrolment or further trial delays would also weaken the rationale for paying upfront to obtain a supposedly Phase 2-ready programme.

Dimerix has improved its strategic position by adding a differentiated asset, preserving a renal focus and creating an earlier clinical catalyst ahead of ACTION3 completion. What remains unresolved is whether the company can control development expenditure, overcome the programme’s earlier delay and retain sufficient economics after milestone and royalty payments.

The acquisition thesis will be strengthened by on-time first-patient dosing and credible interim efficacy data in 2027. It will be weakened if Phase 2 preparation consumes substantially more time or capital than anticipated while DMX-200 continues toward its own decisive 2028 endpoint.

Key takeaways from Dimerix’s acquisition of Phase 2-ready DMX-652

• Dimerix has acquired global ownership and development control of DMX-652 from Mission Therapeutics.
• The company will pay US$5 million upfront, with additional contingent development, approval and sales payments.
• DMX-652 is a selective USP30 inhibitor intended to support the removal of damaged mitochondria from injured cells.
• The initial Phase 2 study will evaluate approximately 160 patients at high risk of acute kidney injury following cardiac surgery.
• The Food and Drug Administration has cleared the trial protocol under an open United States Investigational New Drug application.
• Dimerix expects site initiation in the second half of 2026, first-patient dosing in the first half of 2027 and interim data during 2027.
• The acquisition creates a nearer-term clinical catalyst while the DMX-200 ACTION3 Phase 3 trial continues toward completion in 2028.
• Dimerix said the upfront acquisition payment and initiation of the Phase 2 trial are funded through cash, partner payments and an available A$10 million facility.
• The programme previously received regulatory clearance in 2023 but did not begin on Mission Therapeutics’ original timetable.
• The most important evidence will be timely trial activation followed by clinical data showing that USP30 inhibition reduces acute kidney injury incidence.